GlobeNewswire Inc | Nov 9, 2020 07:05AM EST

November 09, 2020

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,today announced that the company will present at the following upcoming virtual investor conferences.

H.C. Wainwright 6th Annual Israel Conference

Speaker: Dr. Alon Seri-Levy, Chief Executive OfficerFormat: Corporate PresentationDate: November 12, 2020Time: 8:30 AM ET

Jefferies Virtual London Healthcare Conference

Speakers: Dr. Alon Seri-Levy, Chief Executive Officer Gilad Mamlok, Chief Financial Officer John Vieira,U.S.Head of CommercializationFormat: Fireside ChatDate: November 18, 2020Time: 5:00 PM GMT

A live webcast of the presentations will be available under the Events and Presentations in the investors section of the Companys website at www.sol-gel.com.

About Sol-Gel TechnologiesSol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea. The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visitwww.sol-gel.com.

For further information, please contact:Sol-Gel Contact:Gilad MamlokChief Financial Officer+972-8-9313433

Investor Contact:Lee SternSolebury Trout +1-917-312-5998lstern@soleburytrout.com

Source: Sol-Gel Technologies Ltd.